These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effect of prostaglandin F2alpha on the luteal phase of the cycle in nonpregnant women.
    Author: Arrata WS, Chatterton RT.
    Journal: Am J Obstet Gynecol; 1974 Dec 01; 120(7):954-9. PubMed ID: 4429112.
    Abstract:
    11 healthy nonpregnant female volunteers were treated with (PGF) prostaglandin F2alpha as the THAM salt in aqueous solution administratered intravaginally. (HCG) Human chorionic gonadotropins was also administered to 9 of these women prior to or following the PG therapy to simulate secreting the phoblast. It was considered that luteolysis occurred if serum progestin declined to preovulatory levels, if there was no increase of serum progestin levels following HCG, and if there was shortening of the menstrual cycle by at least 3 days. Plasma LH, progesterone, 17-hydroxyprogesterone, 20alpha dihydroprogesterone, and PG were measured by radioimmunoassay techniques. When administered early in the luteal phase, PGF2alpha did not alter the length of the cycle. When administered in midluteal phase followed by HCG, there was an increase in cycle length and in serum progesterone levels. If no HCG was given, the cycle length was increased after PGF2alpha. When administered late in the cycle, the progesterone levels rose, but the cycle length remained unaltered despite HCG. The PG plasma levels varied significantly among the patients despite a uniform route/dose administration. However, with low plasma levels, there was evidence of increased progesterone production, while with high plasma levels, progesterone output rapidly diminished. The side effects accompanying elevated PGF2alpha plasma levels were pronounced.
    [Abstract] [Full Text] [Related] [New Search]